Notification for least-developed countries under Canada's Access to Medicines Regime

Least-developed countries, as identified on Schedule 2 to Canada's Patent Act, planning to use Canada's Access to Medicines Regime are required to notify

• the World Trade Organization (WTO), if they are a member of the WTO (model notification letter); or
• the Government of Canada, if they are not a member of the WTO (model notification letter).

For instructions on how to provide notice, see Notifying the World Trade Organization or Notifying the Government of Canada.

Countries must disclose the following information to the appropriate authority when planning to use the Regime:

• The name and quantity of the drug or medical device needed; and
• A declaration that the product is not patented in the importing country; or
• If the product is patented in the importing country, a declaration that the country will or has issued a compulsory licence authorizing it to use the product.

Least-developed countries that are not members of the WTO are also required to declare that they will adopt measures to prevent diversion of the products to unintended markets.

For a graphic illustration of the notification process, see the process map for Schedule 2 countries.